

BIOCAPTIVA Appoints Frank Armstrong and Stephen Little to its Board of Directors

- *Dr Frank Armstrong MBChB currently works as an Independent Advisor, Chairman and Board Member to several life science companies*
- *Dr Stephen Little PhD is an experienced diagnostics executive and entrepreneur, co-founder of DXS Limited*

Edinburgh, UK – April 21, 2021 – BIOCAPTIVA Ltd (“BIOCAPTIVA”), a company developing the BioCaptor, a revolutionary cell free DNA (cfDNA) capture device, which has the potential to transform liquid biopsy testing for cancer management, announces the appointment of Frank Armstrong as Chair and Stephen Little to its Board of Directors.

Dr Frank Armstrong MBChB

Dr Armstrong has over 40 years’ experience in the biopharmaceutical industry currently serving as a consultant, Chairman and Board member to several life science companies. Frank began his career leading product development strategies, at companies including Zeneca Pharmaceuticals (now AstraZeneca plc) and Bayer, where he led successful product approvals for the US and EU across a range of therapeutic areas before going on to serve as CEO at five biotechnology companies.

Frank has been the responsible Chairman for a successful NASDAQ listing (Summit), three successful AIM listings (Redx Pharma, Faron Pharmaceuticals and Mereo Biopharma) and for a \$100M investment in Cardiorentis. Frank’s Board level experience extends to the US where he has overseen the acquisitions of Xcleron by Pharmaron and Juniper Pharma by Catalent.

Frank holds a MBChB, Bachelor of Medicine, Bachelor of Surgery from the University of Edinburgh. He is a Fellow of the Royal College of Physicians of Edinburgh and Non-Executive Director of the University of Edinburgh’s governing body, the University Court.

Dr Stephen Little PhD

Dr Little has an extensive medical companion diagnostic background, leading research and development teams in the diagnostic divisions of ICI and AstraZeneca, in addition to holding executive roles at DxS, QIAGEN and Yourgene Health (formerly Premaitha).

Stephen is a successful entrepreneur, having co-founded and served as CEO for DxS Limited, a company which launched the first companion diagnostic product to predict drug response in cancer patients. DxS was sold to QIAGEN for \$130m where Stephen went on to lead the global Companion Diagnostics Partnerships team as Vice President of Personalised Healthcare. Stephen also served as CEO for Premaitha which launched the first in vitro diagnostic product for non-invasive prenatal testing (NIPT) following IPO in 2014. Stephen now holds the role of Executive Vice Chairman at Yourgene (formerly Premaitha) alongside Non-Executive Director for ClinspecDx.

Stephen holds a PhD in Microbiology from Heriot-Watt University.

“I am delighted to welcome both Frank and Stephen to BIOCAPTIVA’s Board” said **Jeremy Wheeler, CEO of BIOCAPTIVA**. “Their combined industry expertise, diagnostic R&D background and leadership experiences will be invaluable to BIOCAPTIVA as we look to progress the BioCaptor technology with the aim to revolutionise the liquid biopsy market. I look forward to working with both of them to advance this highly promising product.”



About BIOCAPTIVA

BIOCAPTIVA is developing the BioCaptor, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The BioCaptor captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients.

BIOCAPTIVA was founded in 2021 when it spun out from the University of Edinburgh. BIOCAPTIVA is based in Edinburgh and backed by Archangels and Scottish Enterprise.

For more information, please visit www.biocaptiva.com

LinkedIn: www.linkedin.com/company/biocaptiva-limited/

Contacts

Jeremy Wheeler
Chief Executive Officer
info@biocaptiva.com
www.biocaptiva.com

Media Relations for BIOCAPTIVA Ltd

David Dible, Eleanor Perkin, Frazer Hall MEDiSTRAVA Consulting
+44 (0)20 7638 9571
biocaptiva@medistrava.com